Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030193 (pain)
 261,466 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

253 patients with acute pancreatitis were treated in clinic for surgery in Zagreb through last 23 years. The most frequent cause of pancreatitis were diseases of biliary tract, obesity, vascular deseases, alcoholism etc. In the symtomatology, the pain was present in all patients and majority of them had abdominal symptoms as well. Most of the patients came to the treatment within the firsts 24 to 48 hours. Besides Trasylol various conservative therapy was applied and some patients were operated either on billiary ducts or on pancreas. 85 patients had to be operated again on billiary tract afterwards. From 253 patients treated 24 died (9,48%) because of the necrosis of pancreas and alterations on various other organs.
 ...
PMID:[253 patients with acute pancreatitis treated at the surgical clinic in Zagreb]. 30 Sep 70

2 fibrinolytic inhibitors were evaluated in IUD-wearing women complaining of menorrhagia and spotting to determine if direct application into the uterus could reduce such side effects of IUD wear. The agents used were the proteinase inhibitor transexamic acid (AMCA) and a naturally occurring pancreatic trypsin inhibitor Trasylol. Solutions of the antifibrinolytic agents (1 gm/ml AMCA and 19 gm/ml Trasylol) were injected into th eue rine cavity. 10 of the women acted as control. Both agents reduce the length of the menstrual period by about 50% with a significant reduction in pain and vaginal discharge. This effect was usually sustained over several menstrual cycles. Local administration is more advantageous than the oral approach because smaller dosage is required and side effects thus reduced. It is suggested that proteinase inhibitors be incorporated directly into IUDs.
 ...
PMID:Hemorrhage induced by intrauterine devices: control by local proteinase inhibition. 59 May 49

Twenty patients with peripheral arterial disease and 10 normal controls were submitted to i.v. injection of aprotinin, polypeptide (mol.wt. 6512) extracted from bovine lung, in order to examine its effects on: (a) lower limbs pain, (b) lower limbs sensibility, (c) calf blood flow. Aprotinin (100,000 Ku i.v. diluted in NaCl 0.9%) was given in a single dose or twice a day for a week; for control the same subject received, before or after aprotinin, an equivalent volume of diluent (0.9% NaCl). The results demonstrate that aprotinin is able to increase the initial pain limit walking tolerance and to decrease the intensity of pain at rest and of myalgic or "trigger" areas. No variation was observed on skin sensibility and on calf blood flow, both basal resting and hyperemic. The favorable effect of examined polypeptide on ischemic pain can be attributed neither to increase of calf blood flow nor to influence on perception of painful stimuli. It seems therefore to suggest that aprotinin acts on biochemical mechanisms that cause the ischemic pain. Presumably it inhibits kininogenases and tissue protein-hydrolyzine enzymes activated in the course of ischemia.
Pain 1975 Dec
PMID:Effect of a proteinase inhibitor on intermittent claudication or on pain at rest in patients with peripheral arterial disease. 108 49

The release of glandular kallikrein into the interstitium of the parotid gland appears to play an important role in the occurrence of the inflammatory interstitial edema in chronic recurrent parotitis. This provides fresh impetus for the treatment of this parotid disease with a kallikrein inhibitor. In our present study, seven patients with acute exacerbated chronic recurrent parotitis were treated with the kallikrein inhibitor aprotinin (Trasylol, Bayer AG, Leverkusen). With this therapy all patients were free of pain 12 h after the start of the therapy and most salivary gland function had returned to normal by 48 h after beginning treatment. Within this period of time, concomitant swelling of the affected parotid gland disappeared completely in five patients and resolved in the other two patients after 1 week.
 ...
PMID:New concepts in the treatment of chronic recurrent parotitis. 241 5

Excessive release of glandular kallikrein into the interstitial space around the salivary gland ducts plays a significant role in chronic recurrent parotitis. In the present study 26 patients suffering from acute exacerbated chronic recurrent parotitis were subjected to treatment with the kallikrein inhibitor aprotinin (Trasylol, Bayer AG). During the first hour of treatment 1 mio KIU Aprotinin were infused intravenously, followed by 250 000 KIU/h for another 35 h. Within 12 h after initiation of therapy in all patients we observed remission of pain. Salivary gland function which had been seriously impaired prior to therapy was found to be largely normalized within 48 h in most patients treated in this way. The success of this therapy schedule underlines the suggestion that glandular kallikrein is a trigger enzyme in the pathogenesis of chronic recurrent parotitis.
 ...
PMID:[Treatment of chronic recurring parotitis with the protease inhibitor aprotinin (trasylol)]. 242 32

A group of 159 dogs divided in 8 sub-groups were studied, in regard to pancreatitis, the purpose of the study was to investigate the participation of the automatic nervous system in the course of acute pancreatitis. The procedures and the results were as follows: 1. Pancreatitis was induced in two forms: a) Injection of gallbladder bile, from the same animal to the pancreatic duct. b) Blind duodenal loop with exclusion of the distal duodenum through the pylorus. In both cases acute pancreatitis was obtained. Fat necrosis was predominant in type a, and hemorrhagic lesions in type b. 2. The anesthetic block of the celiac plexus controlled the pain and shock. The animals were in good general conditions but there were no changes in the pathological process of the pancreas. The same results were noted in surgical resections of splanchnic trunks. 3. When the surgical resections of splanchnic nerves was followed by a waiting period of 20 days from the production of pancreatitis there were no changes in the gland. 5. Vagotomy previous to pancreatitis does not have protector effects in the induction of pancreatitis. 6. Continuous perfusion of E.V. novocaine was of extreme utility. The animals remained without pain and the process remained stable when it was given in the initial face of edema. 7. The enzyme inhibitor (Trasylol) given in the first 24 hs. does not prove to be valuable. Due to the fermentative derangement the condition of the animals was better maintained in relation to the comparative animals.
 ...
PMID:[Acute pancreatitis. Neurovascular and microcirculatory changes. Pathogenic and therapeutic study]. 246 25

In an experimental and clinical study a significant reduction of the postoperative edema after extracorporeal extremity perfusion under addition of Aprotinin was observed. Together with reduction of edema usually expected complications like pain and peripheral nerve damage could be reduced significantly. Preliminary, yet unpublished data on cytostatic infusion of the pancreas also indicate that intraarterial Aprotinin when given simultaneously may prevent pancreatitis. It is mandatory Aprotinin to be given early enough in sufficiently high dose and there seems to be an advantage when the arterial route is used.
 ...
PMID:Inhibition of proteases during extracorporeal extremity perfusion experimental and clinical results. 246 10

An objective method for evaluating the cause of pain in hip arthroplasty was investigated in patients with a radiolucent zone of less than 2 mm at the cement-bone interface or the cement-stem or socket interface. Eight patients with a McKee-Farrar total hip prosthesis followed up for an average of 102 months and 20 patients with a Charnley total hip prosthesis observed for an average of 43 months were studied. Different components of the implant materials, such as cement monomer, BaSO4, ceramic, acrylic cement, stainless steel and high-density polyethylene, (HDP) were exposed to normal plasma. Contact activation of plasma was found to occur for all materials, except for HDP, yielding plasma kallikrein. The induced prekallikrein activation was markedly reduced in vitro by Trasylol. There was a significant increase in plasma kallikrein activity in the patients with discomfort and/or pain without gross loosening compared with the patients with pain-free hip arthroplasties. Furthermore, statistically significant enhancement of the kallikrein activity was observed in plasma from the femoral vein at the site of operation compared with that from the cubital vein of the same subject. The enhanced plasma kallikrein activity in the patients gradually decreased, as did the clinical symptoms, when Trasylol was administered. It is concluded that measurement of plasma kallikrein activity may produce useful information about the process of total hip arthroplasty and provide an objective evaluation of pain.
 ...
PMID:An objective examination for painful hip after total hip arthroplasty. 617 85

ASA is commonly used for many years as pain relief drug, anti-inflammatory and against temperature, as well as antiaggregatory agent in coronary disease therapy. Aprotinin (Trasylol) has antifibrinolytic properties, among other actions, inhibits intrinsic coagulation cascade, and it has been demonstrated to reduce blood loss. Can be given in different doses and by different protocols. It is frequently used in cardiosurgery to reduce postoperative bleeding in the cases when ASA is not stopped at the right time before surgery. We evaluated the effects of therapeutic ASA doses on postoperative bleeding in patients undergoing coronary bypass grafting (CABG) compared with usage of Trasylol in CABG, bleeding and blood and fresh frozen plasma (FFP) requirements. This is a retrospective study, period October 1998-March 2002. Out of total CABG patients 75 fulfilled criteria (elective surgery, first CABG)--they were divided into following groups: ASA group of 25 patients (ASA withdrawn 1-3 days before surgery), Non ASA group of 25 patients (ASA withdrawn 10 or more days before surgery) and Trasylol group of 25 patients (ASA till surgery plus Trasylol intraoperatively). Average bleeding in ASA group 24 hours postoperatively was 1600 ml, Non ASA group had average bleeding 900 ml, while Trasylol group had average drainage of 700 ml after 24 hours. ASA average blood requirement was 1800 ml, 250 ml FFP and 250 ml 5% albumin, Non ASA group has less need for blood and FFP--250 ml blood, 50 ml FFP and 30 ml 5% albumin. Our Trasylol group had quite profound bleeding and high requirements for blood and FFP--average 850 ml blood, 200 ml FFP and 150 ml 5% albumin. We recommend discontinuation of ASA therapy sufficiently early for all elective CABG, because in our case Trasylol did not give satisfactory decrease in postoperative bleeding and blood and FFP requirements. That all increase possibility of postoperative complication occurrence and increase CABG costs.
 ...
PMID:[To what extent does Trasylol decrease the need for blood and blood derivatives in postoperative acetylsalicylic acid (ASA)-induced hemorrhage in CABG surgery?]. 1501 65

Pulmonary injury during cardiopulmonary bypass is common as patient factors (smoking, pain, pneumonia) and the effects of cardiopulmonary bypass combine to compromise lung function after cardiac surgery. Lung injury follows the propagation of an inflammatory response involving cytokines, complement, neutrophils, monocytes, activated endothelial cells and platelets. Neutrophils sequester in the lung in response to chemotactic agents and release injurious oxygen free radicals and specific enzymes resulting in widespread pulmonary injury. To alleviate this lung injury a number of possible interventions exist. Off pump surgery may reduce the degree of systemic inflammation but respiratory impairment still occurs and the clinical advantage is uncertain. The use of leukocyte filtration can attenuate the acute inflammatory response with encouraging though variable results. Aprotinin, Pentoxyfilline, Nitric oxide, Aspirin and other agents have shown benefits in lung function after cardiopulmonary bypass induced lung injury. Given the magnitude and diversity of the inflammatory response to cardiopulmonary bypass many possible interventions exist to attenuate lung injury resulting from extracorporeal circulation. Immediate clinical benefits are likely to result from successful amelioration of the processes involved.
 ...
PMID:Lung injury after cardiopulmonary bypass. 1693 16


1